Zobrazeno 1 - 10
of 803
pro vyhledávání: ''
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Autor:
Sudeep Banerjee, Robert J. Wechsler-Reya, Jill P. Mesirov, Alexander T. Wenzel, Hyunho Yoon, Huwate Yeerna, Chih-Min Tang, Mayra Yebra, Pablo Tamayo, Stephanie Ting, Jason K. Sicklick
Publikováno v:
Molecular Cancer Therapeutics. 20:2035-2048
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high
Autor:
Shaima’a Hamarsheh, Justus Duyster, Lukas Braun, Franziska M. Uhl, Sandra Duquesne, Geoffroy Andrieux, Robert Zeiser, Melanie Boerries, Annette Schmitt-Graeff, Lena Osswald, Christine Dierks, Tilman Brummer, Claudius Klein
Publikováno v:
Molecular Cancer Research. 19:1596-1608
The bone marrow microenvironment (BMME) is key player in regulation and maintenance of hematopoiesis. Oncogenic RAS mutations, causing constitutive activation of multiple tumor-promoting pathways, are frequently found in human cancer. So far in hemat
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Linda A. deGraffenried, Aleksandra Gruslova, Andrew Brenner, Christopher A. Jolly, Bryan Mcclellan
Publikováno v:
Cancer Research. 81:PS17-26
INTRODUCTION: Estrogen receptor-positive (ER+) breast cancer accounts for nearly 70% of all cases. Common targeted anti-estrogen therapies such tamoxifen, fulvestrant and aromatase inhibitors have shown success in the clinic, but unfortunately, often
Autor:
Winfried R. Mulder, Lisa D. Eli, Neil T Conlon, Denis M. Collins, Suzanne J.C. van Gerwen, Alshad S. Lalani, Jeffrey J. Kooijman, Irmina Diala, John Crown, Guido J.R. Zaman
Publikováno v:
Cancer Research. 81:PS10-06
Introduction: Human epidermal growth factor 2 (HER2/ERBB2) is frequently amplified or mutated across various cancer types. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive b
Autor:
Carsten Sticht, Carolin Mogler, Olga Ermakova, Fabian Rose, Stefan Thomann, Eduard Ryschich, Carolina De La Torre, Daniel Kazdal, Kai Breuhahn, Claudia R. Ball, Norbert Gretz, Stephanie Roessler, Simone Marquard, Sarah Fritzsche, Peter Schirmacher, S Weiler, Teng Wei, Eugen Rempel, Hanno Glimm, Marcell Tóth
Publikováno v:
Cancer Research. 80:5502-5514
The oncogene yes-associated protein (YAP) controls liver tumor initiation and progression via cell extrinsic functions by creating a tumor-supporting environment in conjunction with cell autonomous mechanisms. However, how YAP controls organization o
Publikováno v:
Cancer Research. 80:3945-3958
Malignant glioma constitutes one of the fatal primary brain tumors in adults. Such poor prognosis calls for a better understanding of cancer-related signaling pathways of this disease. Here we elucidate a MYC-miRNA-MXI1 feedback loop that regulates p
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Kei-ichiro Arimoto, Leo J.Y. Kim, Balázs Győrffy, Klaus-Peter Knobeloch, Dong-Er Zhang, Hua Cheng, Christoph Burkart, Xiang-Dong Fu, Jeremy N. Rich, Hu Cang, Jun-Bao Fan, Yu Zhou, Hui-Zhong Xu, Ming Yan, Sayuri Miyauchi, Dan Liu
Publikováno v:
Cancer Discov
Type I interferons (IFN), which activate many IFN-stimulated genes (ISG), are known to regulate tumorigenesis. However, little is known regarding how various ISGs coordinate with one another in developing antitumor effects. Here, we report that the I